NCT03189615View on ClinicalTrials.gov

Study Investigating the Pharmacokinetic Properties of the Drug Lu AF35700 in Subjects With Liver Impairment and in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 14, 2017

Primary Completion Date

February 28, 2018

Study Completion Date

April 23, 2018

Conditions
Hepatic Impairment
Interventions
DRUG

Lu AF35700

Single oral dose of 10 mg Lu AF35700

Trial Locations (1)

Unknown

APEX, Munich

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT03189615 - Study Investigating the Pharmacokinetic Properties of the Drug Lu AF35700 in Subjects With Liver Impairment and in Healthy Subjects | Biotech Hunter | Biotech Hunter